Silverfin false false 31/03/2024 01/10/2023 31/03/2024 Mrs Polly Amos 24/04/2014 Dr Richard Cockshott 24/04/2014 Mr Terence Dooley 24/04/2014 Mrs Susan Dooley 24/04/2014 Dr Jan Knobloch 31/05/2022 Dr Emmelne Maguire 31/05/2022 Dr Paula Marrett 24/04/2014 Mr Kristian Soderman 24/04/2014 Mrs Jill Waldron 21/03/2017 Dr Michael Waldron 24/04/2014 16 October 2024 The principal activity of the company is the provision of medical research work. 09009007 2024-03-31 09009007 bus:Director1 2024-03-31 09009007 bus:Director2 2024-03-31 09009007 bus:Director3 2024-03-31 09009007 bus:Director4 2024-03-31 09009007 bus:Director5 2024-03-31 09009007 bus:Director6 2024-03-31 09009007 bus:Director7 2024-03-31 09009007 bus:Director8 2024-03-31 09009007 bus:Director9 2024-03-31 09009007 bus:Director10 2024-03-31 09009007 core:CurrentFinancialInstruments 2024-03-31 09009007 core:CurrentFinancialInstruments 2023-09-30 09009007 2023-09-30 09009007 core:ShareCapital 2024-03-31 09009007 core:ShareCapital 2023-09-30 09009007 core:RetainedEarningsAccumulatedLosses 2024-03-31 09009007 core:RetainedEarningsAccumulatedLosses 2023-09-30 09009007 bus:OrdinaryShareClass1 2024-03-31 09009007 2023-10-01 2024-03-31 09009007 bus:FilletedAccounts 2023-10-01 2024-03-31 09009007 bus:SmallEntities 2023-10-01 2024-03-31 09009007 bus:AuditExempt-NoAccountantsReport 2023-10-01 2024-03-31 09009007 bus:PrivateLimitedCompanyLtd 2023-10-01 2024-03-31 09009007 bus:Director1 2023-10-01 2024-03-31 09009007 bus:Director2 2023-10-01 2024-03-31 09009007 bus:Director3 2023-10-01 2024-03-31 09009007 bus:Director4 2023-10-01 2024-03-31 09009007 bus:Director5 2023-10-01 2024-03-31 09009007 bus:Director6 2023-10-01 2024-03-31 09009007 bus:Director7 2023-10-01 2024-03-31 09009007 bus:Director8 2023-10-01 2024-03-31 09009007 bus:Director9 2023-10-01 2024-03-31 09009007 bus:Director10 2023-10-01 2024-03-31 09009007 2022-10-01 2023-09-30 09009007 bus:OrdinaryShareClass1 2023-10-01 2024-03-31 09009007 bus:OrdinaryShareClass1 2022-10-01 2023-09-30 iso4217:GBP xbrli:pure xbrli:shares

Company No: 09009007 (England and Wales)

FOWEY CLINICAL RESEARCH COMPANY LIMITED

Unaudited Financial Statements
For the financial period from 01 October 2023 to 31 March 2024
Pages for filing with the registrar

FOWEY CLINICAL RESEARCH COMPANY LIMITED

Unaudited Financial Statements

For the financial period from 01 October 2023 to 31 March 2024

Contents

FOWEY CLINICAL RESEARCH COMPANY LIMITED

BALANCE SHEET

As at 31 March 2024
FOWEY CLINICAL RESEARCH COMPANY LIMITED

BALANCE SHEET (continued)

As at 31 March 2024
31.03.2024 30.09.2023
£ £
Current assets
Debtors 3 3,806 3,341
Cash at bank and in hand 25,208 43,114
29,014 46,455
Creditors: amounts falling due within one year 4 ( 24,551) ( 44,305)
Net current assets 4,463 2,150
Total assets less current liabilities 4,463 2,150
Net assets 4,463 2,150
Capital and reserves
Called-up share capital 5 1,250 1,250
Profit and loss account 3,213 900
Total shareholders' funds 4,463 2,150

For the financial period ending 31 March 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Fowey Clinical Research Company Limited (registered number: 09009007) were approved and authorised for issue by the Board of Directors on 16 October 2024. They were signed on its behalf by:

Dr Michael Waldron
Director
FOWEY CLINICAL RESEARCH COMPANY LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial period from 01 October 2023 to 31 March 2024
FOWEY CLINICAL RESEARCH COMPANY LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial period from 01 October 2023 to 31 March 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial period and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Fowey Clinical Research Company Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Fowey River Practice, Rawlings Lane, Fowey, PL23 1DT, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Reporting period length

The company shortened it's year end to align this with the year end of the Fowey River Practice partnership and the tax year, as a result of the ongoing changes in connection with the tax basis period reform.

Turnover

Turnover is stated net of VAT and trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer.

Turnover from the sale of goods is recognised when the goods are physically delivered to the customer.

Taxation

Current tax
Tax is recognised in profit or loss, except that a change attributable to an item of income or expense
recognised as other comprehensive income is also recognised directly in other comprehensive
income.
The current corporation tax charge is calculated on the basis of tax rates and laws that have been
enacted or substantively enacted by the reporting date in the countries where the company operates
and generates taxable income.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets receivable within one year, such as trade debtors and bank balances, are measured at transaction price less any impairment.

Basic financial assets receivable within more than one year are measured at amortised cost less any impairment.

Basic financial liabilities
Basic financial liabilities that have no stated interest rate and are payable within one year, such as trade creditors, are measured at transaction price.

Other basic financial liabilities are measured at amortised cost.

2. Employees

Period from
01.10.2023 to
31.03.2024
Year ended
30.09.2023
Number Number
Monthly average number of persons employed by the Company during the period, including directors 0 0

3. Debtors

31.03.2024 30.09.2023
£ £
Trade debtors 3,556 3,091
Other debtors 250 250
3,806 3,341

4. Creditors: amounts falling due within one year

31.03.2024 30.09.2023
£ £
Amounts owed to directors 104 104
Accruals 2,480 1,190
Taxation and social security 4,452 1,569
Other creditors 17,515 41,442
24,551 44,305

5. Called-up share capital

31.03.2024 30.09.2023
£ £
Allotted, called-up and fully-paid
1,250 ordinary shares of £ 1.00 each 1,250 1,250